Crescent Biopharma filings document a clinical-stage oncology biotechnology issuer with ordinary shares listed on Nasdaq. The company’s Form 8-K reports furnish quarterly and annual financial results, business highlights, and pipeline updates involving CR-001, ADC programs, and collaboration activity.
Its SEC record also includes a definitive proxy statement covering governance, executive compensation, equity awards, shareholder voting matters, and board-related disclosures. Registration statement materials describe the company’s business, capitalization, preferred stock, warrants, convertible instruments, risk factors, and public-company structure.
Crescent Biopharma reported Q2 2026 results with R&D expenses of $19.4 million and G&A expenses of $8.7 million, leading to a net loss of $24.8 million, or $0.74 per share, compared with a $21.8 million loss a year earlier. The company is advancing its oncology pipeline, including the ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody, and ADC programs CR-002 and CR-003, with multiple proof-of-concept and combination data readouts expected beginning in 2027.
Cash and cash equivalents were $171.6 million as of June 30, 2026, with pro forma cash of $305.1 million after a July 2026 public offering that generated $143.7 million in gross proceeds. Crescent expects this capital to fund operations into the second half of 2028, with approximately 33.5 million ordinary shares outstanding, or 43.5 million pro forma.
Crescent Biopharma, Inc. received an updated ownership disclosure from Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and principals Peter Harwin and Tomas Kiselak. The group reports beneficial ownership of 6,593,385 Ordinary Shares of Crescent Biopharma, representing 16.50% of the Ordinary Shares outstanding, based on 39,960,923 Ordinary Shares as of July 16, 2026. This position includes 3,601,316 Ordinary Shares, 2,890,000 Ordinary Shares issuable upon conversion of 2,890 Series A Preferred Shares, and 102,069 Ordinary Shares issuable upon exercise of Pre-Funded Warrants, while excluding 2,191,968 additional warrant shares due to beneficial ownership limits.
On July 16, 2026, Fairmount Healthcare Fund II L.P. purchased 853,450 Ordinary Shares at $14.50 per share and Pre-Funded Warrants to purchase 525,897 Ordinary Shares at $14.499 each in an underwritten public offering, for an aggregate purchase price of $20,000,005.60, using working capital. The securities were acquired for investment purposes.
The reporting persons entered into a 60-day Lock-Up Agreement following the final prospectus supplement, restricting sales of Crescent Biopharma securities without underwriters’ consent. The Pre-Funded Warrants carry a $0.001 exercise price, are immediately exercisable, and do not expire, but are subject to a 9.99% beneficial ownership limitation, which can be adjusted up to 19.99% with a 61-day delay. Conversion of the Series A Preferred Shares is capped at 19.99%, automatically dropping to 9.99% if Fairmount and affiliates’ ownership falls to 9.0% or less. Harwin also holds options for 9,023 Ordinary Shares at $15.30 per share that vested on June 2, 2026, but he disclaims beneficial ownership in favor of Fairmount-managed funds.
Fairmount Healthcare Fund II L.P., an entity associated with Crescent Biopharma, indirectly purchased 853,450 Ordinary Shares at $14.50 and Pre-Funded Warrants for 525,897 shares at $14.499 on July 16, 2026. The Pre-Funded Warrants are exercisable at $0.001 per share, have no expiration, and are subject to a 9.99% beneficial ownership cap.
After these purchases, Fairmount Healthcare Fund II L.P. indirectly held 3,601,316 Ordinary Shares and Pre-Funded Warrants for 2,294,037 shares. Fairmount Funds Management LLC, Peter Harwin, and Tomas Kiselak disclaim beneficial ownership beyond their pecuniary interest.
Crescent Biopharma, Inc. entered into an underwriting agreement for an underwritten public offering of ordinary shares and pre-funded warrants. The company is issuing 8,094,793 ordinary shares at $14.50 per share and, for certain investors, pre-funded warrants to purchase an aggregate of 525,897 ordinary shares at $14.499 per warrant.
The underwriters have a 30-day option to buy up to 1,293,103 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds are expected to be approximately $125.0 million, with estimated net proceeds of about $115.9 million, or $133.5 million if the option is fully exercised. The offering is expected to close on July 16, 2026, subject to customary conditions.
Each pre-funded warrant has a $0.001 exercise price, is immediately exercisable, does not expire, and includes beneficial ownership limitations of 4.99%, 9.99% or 19.99%. Crescent expects the net proceeds, together with existing cash, to fund operating, working capital and capital expenditure needs into the second half of 2028.
Crescent Biopharma, Inc. is conducting a primary offering of 8,094,793 ordinary shares and 525,897 pre-funded warrants to purchase ordinary shares at $14.50 per share and $14.499 per pre-funded warrant, for a public offering size of $124,999,479. Underwriters hold a 30-day option to buy up to 1,293,103 additional ordinary shares.
The company expects net proceeds of approximately $115.9 million (or $133.5 million if the option is fully exercised), to fund clinical development of oncology candidates CR-001, CR-002 and CR-003, CMC activities, preclinical programs, and general corporate purposes. Net tangible book value per share will rise from $6.67 to $8.40, implying dilution of $6.10 per new share at the offering price. Management preliminarily estimates cash and cash equivalents of approximately $171.6 million as of June 30, 2026, and believes existing cash plus this raise will fund projected needs into the second half of 2028.
Crescent Biopharma, Inc. provides a preliminary estimate that cash and cash equivalents were approximately $171.6 million as of June 30, 2026. The figure is unaudited, based on management estimates for the quarter, and may change after completion of financial closing procedures.
The company states that its independent auditor, PricewaterhouseCoopers LLP, has not audited, reviewed, examined, compiled or applied procedures to this data. The information is treated as filed under Section 18 of the Exchange Act and incorporated by reference into certain securities law filings, and is accompanied by forward-looking statement cautions.
Crescent Biopharma, Inc. is raising capital through a public offering of ordinary shares and pre-funded warrants under an effective shelf registration. The company is a clinical-stage oncology business developing its lead bispecific antibody CR-001 and antibody-drug conjugates CR-002 and CR-003 in Phase 1/2 trials.
The offering consists of newly issued ordinary shares listed on Nasdaq Capital Market under “CBIO” and, in lieu of shares for some investors, pre-funded warrants priced at the share offering price minus $0.001, with a $0.001 exercise price. The warrants are exercisable at any time until fully exercised, subject to ownership caps, but will not be listed and may be illiquid.
As of June 30, 2026, Crescent estimates cash and cash equivalents of approximately $171.6 million and expects existing cash, before this raise, to fund operations into 2028. Net proceeds are intended to support clinical development of CR-001, CR-002 and CR-003, chemistry and manufacturing activities, preclinical research, and general corporate purposes. Investors face immediate and substantial dilution, with additional potential dilution from extensive outstanding options, warrants, preferred shares and a $200 million at-the-market program, alongside risks specific to the pre-funded warrants and complex U.S. tax treatment.
Crescent Biopharma, Inc. filed a shelf registration to offer up to $500,000,000 of securities and a sales agreement prospectus to sell up to $200,000,000 of ordinary shares under an Open Market Sale agreement with Jefferies LLC.
The $200 million sales agreement amount is included in the $500 million shelf; offerings are subject to completion and may be sold from time to time in one or more offerings. The prospectus notes the company’s ordinary shares trade on Nasdaq under the symbol CBIO, with a last reported sale price of $18.00 per share on June 30, 2026.
CRESCENT BIOPHARMA, INC. officer Ryan Lynch reported an open-market sale of 465 Ordinary Shares on June 22, 2026 at a weighted average price of $17.99 per share. These shares were automatically sold to satisfy tax withholding obligations tied to the settlement of restricted stock units granted on December 15, 2025, under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026. Following this tax-related sale, Lynch directly holds 13,871 Ordinary Shares.